ThermoGenesis Holdings (NASDAQ:THMO) along with its joint venture, ImmuneCyte plans to roll out a comprehensive diagnostic and therapeutic product line to fight COVID-19 pandemic.
The multi-pronged strategy will combine diagnostic, therapeutic and service offerings to better detect, track and fight coronavirus. Further details will be included in the company’s presentation at the LD Micro 500 Conference today at 5 p.m. EST.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.